Clinical Evaluation and Safety of Loxiglumide (CCK-A Receptor Antagonist) in Nonresectable Pancreatic Cancer Patients
スポンサーリンク
概要
- 論文の詳細を見る
- 1997-04-01
著者
-
Militello Carmelo
Department Of Surgery University Of Padua Hospital Of Cittadella
-
Pedrazzoli Sergio
Department Of Medical And Surgical Sciences Surgical Semeiotics
-
Pedrazzoli Sergio
Department Of Surgery University Of Padua Hospital Of Cittadella
-
SPERTI Cosimo
Department of Surgery, University of Padua, Hospital of Cittadella
-
DI PRIMA
Department of Radiology, Hospital of Cittadella
-
the Italian
Department of Surgery, University of Padua, Hospital of Cittadella
-
Di Prima
Department Of Radiology Hospital Of Cittadella
-
Sperti Cosimo
Department Of Medical And Surgical Sciences Iv Surgical Clinic University Of Padova
-
Sperti Cosimo
Department Of Surgery University Of Padua Hospital Of Cittadella
-
The Italian
Department Of Surgery University Of Padua Hospital Of Cittadella
-
Pedrazzoli Sergio
Department Of Medical And Surgical Sciences Iv Surgical Clinic University Of Padova
関連論文
- Putative Pancreatic Cancer-Associated Diabetogenic Factor : 2030 MW Peptide
- Clinical Evaluation and Safety of Loxiglumide (CCK-A Receptor Antagonist) in Nonresectable Pancreatic Cancer Patients
- Duodenum-preserving versus pylorus-preserving pancreatic head resection for benign and premalignant lesions
- Parenchyma-sparing resection for pancreatic neoplasms
- Pancreatic Head Resection for Noninflammatory Benign Lesions of the Head of the Pancreas
- Pancreaticoduodenojejunostomy for Chronic Pancreatitis Presenting with an Inflammatory Mass in the Head of the Pancreas